Abstract:Topic: Retinopathy of prematurity (ROP) is a severe retinal vascular disorder affecting preterm infants, potentially leading to retinal detachment and blindness. This review aims to elucidate the relationship between systemic VEGF levels and ROP. Clinical relevance: This systematic review aims to consolidate evidence from available studies to guide future research and inform clinical practice. In particular, the role of circulating VEGF-A levels in predicting ROP onset and progression, and evaluating the impact of anti-VEGF therapy on these levels, is crucial in ensuring efficacy and safety in patient care. Methods: Scopus and PubMed were searched to identify studies investigating circulating VEGF-gene products in ROP patients using immunologic assays. Two authors independently screened the literature and extracted data, employing a random-effects meta-analysis to compare VEGF levels as the ratio of means between ROP patients and controls before and after treatment, heterogeneity was reported by I2-statistics. Risks of bias and publication bias were assessed using Quality Assessment of Diagnostic Accuracy Studies-2 and funnel plots/Egger's tests, respectively. Results: Out of 941 papers, 54 were included, with 26 providing posttreatment data and 31 providing biomarker data. Findings show a significant decrease in VEGF-A levels in the first week after ROP treatment (ratio of means [95% confidence interval] 0.34 [0.25-0.45], I2 = 97%, 17 publications). Anti-VEGF therapy showed a significantly more pronounced decrease (0.31 [0.25-0.38], I2 = 40%, 7 publications) than laser treatment in the first week after treatment (0.77 [0.61-0.97], I2 = 42%, 2 publications, subgroup difference, P < 0.01), among studies with a low risk of bias. Serum samples demonstrated a more marked decrease in VEGF-A than plasma (subgroup difference P < 0.01). However, the use of blood VEGF-A concentration as a biomarker for ROP prediction has shown inconsistent trends. The risk of bias mainly stems from unclear patient selection and lack of sample timing or analytical method details. Conclusion: While anti-VEGF treatment significantly reduced blood VEGF-A levels in the first week post-ROP treatment, blood VEGF-A levels did not consistently predict ROP development. Heterogeneity in the results underscores the need for optimized analytical methods and emphasizes the importance of considering individual variation in VEGF-A concentrations independent of ROP diagnosis. Financial disclosures: The author(s) have no proprietary or commercial interest in any materials discussed in this article.

Correlation Between Apelin and VEGF Levels in Retinopathy of Prematurity: a Matched Case–control Study

Apelin in epiretinal fibrovascular membranes of patients with retinopathy of prematurity and the changes after intravitreal bevacizumab.

Circulating VEGF-A Levels in Relation to Retinopathy of Prematurity and Treatment Effects: A Systematic Review and Meta-Analysis

Vascular Endothelial Growth Factor and Apelin in Plasma of Patients with Retinopathy of Prematurity

Apelin in Plasma and Vitreous and in Fibrovascular Retinal Membranes of Patients with Proliferative Diabetic Retinopathy.

[Expression and Action of Vascular Endothelial Growth Factor and Its Receptor in a Rat Model of Retinopathy of Prematurity].

The Role of Apelin/APJ in a Mouse Model of Oxygen-induced Retinopathy

Plasma apelin and vascular endothelial growth factor levels in preterm infants: relationship to neonatal respiratory distress syndrome.

Expression of Total Vascular Endothelial Growth Factor and the Anti-angiogenic VEGF 165 B Isoform in the Vitreous of Patients with Retinopathy of Prematurity.

Association of serum levels of inflammatory cytokines with retinopathy of prematurity in preterm infants

Elevation of Serum Apelin-13 Associated with Proliferative Diabetic Retinopathy in Type 2 Diabetic Patients.

The Relationship Between Cytokines Serum Levels at Postnatal 4-6 Weeks and Retinopathy of Prematurity

A Good Study about Early Predictive Biomarkers in Severe Retinopathy of Prematurity

Analysis of 218 cases of retinopathy of prematurity

Meta-analysis of the Efficacy and Safety of Anti-vascular Endothelial Growth Factor Inhibitor in the Treat-ment of Retinopathy of Prematurity

Incidence and Risk Factor Analysis of Retinopathy of Prematurity

Progress in the study of association between hematological indicators and retinopathy of prematurity (Review)

Incidence of Retinopathy of Prematurity Treatment in Extremely Preterm Infants in China.

The Prognostic Value Of Lymphocyte-To-Monocyte Ratio In Retinopathy Of Prematurity

Apelin in epiretinal membranes of patients with proliferative diabetic retinopathy.

Analysis of risk factors of retinopathy of prematurity